A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Distal Lateral Subungual Onychomycosis of the Toenail

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Distal Lateral Subungual Onychomycosis of the Toenail

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs VT 1161 (Primary)
  • Indications Onychomycosis
  • Focus Therapeutic Use
  • Acronyms RENOVATE
  • Sponsors Viamet Pharmaceuticals
  • Most Recent Events

    • 27 Jul 2017 According to a Viamet Pharmaceuticals media release, results from this trial will be presented at the American Podiatric Medical Association (APMA) 2017 Annual Scientific Meeting (The National).
    • 21 Jun 2017 According to a Viamet Pharmaceuticals media release, data from this trial will be presented at the 4th International Summit on Nail Diseases 2017.
    • 06 Mar 2017 Results from this trial were presented at the 75th American Academy of Dermatology (AAD) Annual Meeting, according to a Viamet Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top